04:23 PM EST, 02/18/2025 (MT Newswires) -- Halozyme Therapeutics ( HALO ) reported Q4 non-GAAP earnings Tuesday of $1.26 per diluted share, up from $0.82 a year earlier.

Analysts polled by FactSet expected $1.13

Revenue in the three months ended Dec. 31 rose to $298 million from $230 million a year earlier.

Analysts surveyed by FactSet expected $285.7 million.

The company reiterated 2025 non-GAAP diluted EPS guidance of $4.95 to $5.35 on revenue of $1.15 billion to $1.23 billion.

Analysts polled by FactSet expect EPS of $4.90 on revenue of $1.19 billion.

Shares of the company rose 1.9% in after-hours trading.